Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Q1 FY26 Earnings Presentation
18 slides from Zydus Lifesciences's earnings presentation, Aug 12, 2025
Slide 1: Exchange filing cover letter for Investor Presentation
August 12, 2025 Listing Department Code: 532321 BSE LIMITED P J Towers, Dalal Street, Mumbai–400 001 Listing Department Code: ZYDUSLIFE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, C/1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai–400 051 Re: Investor Presentation Dear Sir, Please f
Slide 2: Earnings Presentation: Q1 FY26
Zydus Lifesciences Limited Earnings Presentation: Q1 FY26 12th August, 2025 1
Slide 3: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement • THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF ZYDUS LIFESCIENCES LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general
Slide 4: Q1 FY26: At a Glance
Q1 FY26: At a Glance Revenues from Highlights of Q1 FY26 R&D Operations ❑ Total revenues registered stable growth of 6% YoY. Rs. 65,737 mn Rs. 4,856 mn ❑ India branded formulations sustained the growth momentum and 6% YoY 7.4% of revenues outpaced the market growth for yet another quarter. ❑ Consume
Slide 5: Key Financial Metrics (1/2)
Key Financial Metrics (1/2) Total Revenues (Rs. mn) Gross Profit (Rs. mn) and Gross Margin % 74.4 % 71.9 % 69.9 % 74.0 % 72.8% 65,279 65,737 62,075 48,308 46,214 47,842 52,370 52,691 37,656 36,857 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Total R&D (Rs. mn) and
Slide 6: Key Financial Metrics (2/2)
Key Financial Metrics (2/2) PAT ex. Exceptional (Rs. mn) Organic Capex (Rs. mn) 14,199 14,668 13,905 4,020 10,235 3,202 3,014 3,017 2,907 9,112 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Net Cash (Rs. mn) Net Working Capital* (Rs. mn) 56,312 71,427 62,596 60,585
Slide 7: India Formulations business
India Formulations business Sustained market outperformance driven by chronic portfolio Highlights for the quarter India Formulations Sales (Rs. mn) Q1 FY26 Revenue ▪ Branded business sustained the growth momentum Contribution and outpaced market growth for yet another quarter. 14,569 15,145 15,394
Slide 8: Consumer Wellness
Consumer Wellness Navigating challenges posed by early monsoon conditions Dominant market share across key brands Consumer Wellness Sales (Rs. mn) Q1 FY26 Revenue Contribution Brand Name Mkt Share % Mkt Rank 9,081 8,549 8,366 33.3%* 1* 4,875 4,488 Facial Cleansing # 7.8%* 5* Scrub 48.7%* 1* Q1 FY25
Slide 9: US Formulations business
US Formulations business Sustained execution excellence with growth on a higher base Highlights for the quarter US Formulations Sales (Rs. mn) Q1 FY26 Revenue Contribution 31,817 ▪ Launched 3 new products. 30,929 31,307 24,168 24,096 ▪ Filed 3 ANDAs and received approval for 6 ANDAs (incl. 2 tentati
Slide 10: International Markets Formulations business
International Markets Formulations business Strong growth on the back of resilient demand across markets Highlights for the quarter IM Formulations Sales (Rs. mn) Q1 FY26 Revenue Contribution 7,265 ▪ All round growth across key geographies driven by strong demand and focused execution. 5,309 5,389 5
Slide 11: Updates on Innovation
Updates on Innovation NCE: Usnoflast • Initiated Phase II(b) clinical trials in the US in patients with ALS. The USFDA granted Fast Track designation to the molecule for ALS indication. The molecule also holds an ODD from the USFDA for this indication. Biotech R&D • Received marketing authorization
Slide 12: Other Updates
Other Updates ▪ Successfully completed stake acquisition in Amplitude Surgical SA, France, a Acquisition of European MedTech leader in high-quality, lower-limb orthopaedic technologies Amplitude Surgical ▪ Amplitude’s portfolio comprises of technologically advanced products and to execute Zydus’ sol
Slide 13: Zydus at a Glance
Zydus at a Glance ~$2.75 bn Global Revenues1 5th Largest generic Co. in US in terms of prescription3 7 R&D Centers For NCE, APIs, Generics, Vaccines Biosimilars and Wellness products Among 1st Revenues from India Approved product for >35% In ~60% of product Geography (Formulations Top 3 families mar
Slide 14: ESG Highlights
ESG Highlights Climate Change (GHG Emissions) Water Management Net Water Neutral by 2028 45% reduction in GHG Intensity by 2030 Creation of water recharge structures in progress 26% GHG Intensity reduction in last three years 19% reduction in water intensity in last three years Net Carbon Neutral by
Slide 15: ESG Ratings
ESG Ratings *Lower the better 14
Slide 16: Consolidated Financial Performance (reported)
Consolidated Financial Performance (reported) Q1 Q1 YoY Q4 QoQ Rs. mn FY26 FY25 gr. FY25 gr. Total Income from Operations 65,737 62,075 5.9% 65,279 0.7% Gross Contribution (GC) 47,842 46,214 3.5% 48,308 -1.0% Gross Margin % 72.8% 74.4% 74.0% Employee benefits expenses* 9,024 7,820 15.4% 8,695 3.8% R
Slide 17: Details of Exchange Rate Fluctuations
Details of Exchange Rate Fluctuations Q1 Q1 YoY Rs. mn FY26 FY25 gr. % A. On operating transactions (above EBITDA line) -500 233 -314.7% a. Included in COGS 71 -19 471% b. Part of other operating expenses (shown separately) -571 252 -327% B. On other income 200 - Total Exchange Rate Fluctuations ('+
Slide 18: Thank you
Thank you For any queries, please contact Arvind Bothra Arvind.Bothra@zyduslife.com +91-22-62711905 For more information, please visit: www.zyduslife.com Registered Office: www.linkedin.com/company/zyduslife Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi C